|
Mar 8
|
What Makes Replimune Group, Inc. (REPL) a New Buy Stock
|
|
Mar 6
|
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
|
|
Mar 5
|
Replimune to Present at Three Upcoming Investor Conferences
|
|
Dec 7
|
An Intrinsic Calculation For Replimune Group, Inc. (NASDAQ:REPL) Suggests It's 24% Undervalued
|
|
Dec 5
|
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers
|